kENUP Foundation: Vaccine Skepticism in Germany Multiplies With Novel COVID Vaccines
11.2.2021 14:35:00 EET | Business Wire | Press release
The first representative study of COVID-19 vaccine skeptics, conducted by kENUP Foundation, the Swiss Academies of Arts and Sciences and the EIB Institute, identified the socioeconomic and consumer behavior profile, as well as the dominant values and positions of COVID-19 vaccines skeptics and examined potential strategies to increase willingness to get a COVID-19 vaccine in that cohort.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210211005455/en/
Most over- and underrepresented characteristics of vaccines skeptics (Graphic: kENUP Foundation)
Overall, 19.6% of the German population make up the COVID-19 vaccine skeptic group, those unlikely or very unlikely to take the jab once offered to them. Almost 84.2% of that group were not opposed to vaccines before the corona crisis. This means that 13.7 million new skeptics are contributing to the high COVID-19 anti-vaccine sentiment.
COVID-19 vaccine skepticism is mainly driven by the fear of long-term damage (66.0%), the fast approval process (54.7%) and fear of adverse health effects (53.0%). It correlates with corona virus denial: 21.7% of vaccine skeptics and 36.8% of long-term anti-vaccinationists disagree that COVID-19 causes serious health problems. Denial of the virus infecting many people worldwide is 21.8% and 40%, respectively for new skeptics and long-term anti-vaccinationists.
While 69.3% of all vaccine skeptics could be convinced to take the COVID-19 vaccine through factual assurances, 69.4% of long-term anti-vaccinationists state that nothing would convince them. On the assurances needed for attitudinal change within the overall cohort, exclusion of long-term damage (52.0%), proven effectiveness (40.8%) and the evidence that genes are not changed (32.0%) top the list. Also, neither celebrity endorsement nor prospects of long-distance travel are convincing skeptics to be vaccinated. Vaccine skeptics seem to have more trust in vaccines originating from Germany, the United States, and the United Kingdom. Vaccines from Russia, China and especially India have a low chance of approval by skeptics.
A prevailing lack of life meaning and political participation defines the cohort of vaccine skeptics: 89.2% feel that they have no influence over politics. Of the long-term anti-vaccinationists, 35.2% express existential fears and financial worries, with life lacking any perspective for 35.6% of them. In terms of political affiliation, the anti-vaccination group is predominantly AfD-leaning (43.0%, far-right), with support of FDP (liberal) and Die Linke (left) also over-represented, while affinity to SPD (centre-left), CDU/CSU (centre-right) and Die Grünen (green) remains significantly underrepresented. Anti-vaccination sentiments are much higher in people of non-Christian religions.
The full report and more information can be found at https://www.kenup.eu/press and https://www.covidx.eu
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005455/en/
Contact information
Press contact
kENUP: Tobias Mac-Lean, maclean@kenup.eu, https://www.kenup.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
